The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma

Published:2020-09 Issue: Volume:108 Page:104935
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Park Jong Chul,Durbeck Julia,Boudadi Karim,Ho Won Jin,Kang Hyunseok^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference7 articles.

1. Camrelizumab (shr-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials;Fang;Lancet Oncol,2018

2. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the keynote-028 study;Hsu;J Clin Oncol,2017

3. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (nci-9742);Ma;J Clin Oncol,2018

4. Recombinant humanized anti-pd-1 monoclonal antibody (js001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase ii clinical study;Wang;J Clin Oncol,2019

5. Phase ii study of spartalizumab (pdr001) vs chemotherapy (ct) in patients with recurrent/metastatic nasopharyngeal cancer (npc);Lim;Cancer Res,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis;Frontiers in Immunology;2023-03-31

2. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial;Annals of Oncology;2023-03

3. Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck;Frontiers in Oncology;2021-09-01

4. Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis;Brazilian Journal of Otorhinolaryngology;2021-04